Business Description
Recce Pharmaceuticals Ltd is an Australian drug company focused on creating new treatments for dangerous bacterial infections, with operations also in the UK and the US. Its main product, RECCE 327, is being tested in multiple clinical trials targeting conditions such as urinary tract infections, skin infections, wound infections, and diabetic foot infections. The company works alongside the Murdoch Children's Research Institute and the US Army's infectious disease research unit to develop treatments for some of the most difficult and hazardous pathogens. Founded in 2007 and based in Sydney, Recce Pharmaceuticals has built a growing pipeline of synthetic anti-infective medicines aimed at addressing serious unmet medical needs.
